From late July 2026, many UAE healthcare deals need merger clearance before they can close.

Cabinet Decision No. 59 of 2026, issued on 20 April 2026, brings the executive regulations to Federal Decree-Law No. 36 of 2023 into force roughly three months after its publication in the Official Gazette. The notification-light regime under Cabinet Decision No. 37 of 2014 is gone. If your platform is buying a hospital, rolling up medical centres, or consolidating a pharma distribution book, the question is no longer whether the deal makes commercial sense. It is whether you can legally complete it on the timeline your investment committee approved.

Notification is mandatory where the parties' combined annual sales in the relevant UAE market exceeded AED 300 million in the previous financial year, or their combined market share exceeds 40% of that market. These triggers, set by Cabinet Resolution No. 3 of 2025, operate as alternatives. Either one is enough on its own. In a narrowly drawn relevant market, such as tertiary care in a single emirate or one therapeutic distribution segment, a 40% share is reached faster than most sponsors assume. Market definition is where these filings are won or lost, and it rewards early, evidenced work rather than a late scramble.

You cannot complete while the review is running. If the regulator does not respond within the statutory period, that silence is treated as a rejection rather than a deemed approval. That single design choice reverses the risk allocation buyers are used to in lighter-touch markets. A gun-jumping close, or an assumption that no news is good news, exposes the transaction to unwinding and penalty risk. Build clearance as a hard condition precedent and price the calendar into the deal from signing.

Once basic transaction details are published on the Ministry's website, interested parties have 15 working days to submit views, evidence or objections. In healthcare, your competitors, unhappy counterparties and large payers know the market and have every incentive to slow a consolidating buyer. Assume your rationale will be read by people who would prefer the deal fail. The answer is a notification file that pre-empts the obvious objections on referral control, pricing power and patient access before they are raised.

The framework lets the regulator establish market power through pricing conduct, barriers to entry and structural features, not share alone. A group sitting at 30 to 35% in a concentrated emirate, with control over scarce licensed capacity or a must-have referral network, can still draw scrutiny. If your investment thesis rests on pricing or network effects, expect those exact strengths to become the regulator's line of inquiry.

DOH Abu Dhabi, the DHA in Dubai and MOHAP federally each control facility licensing and change-of-control consent for the assets you are buying. Those approvals sit alongside the new merger clearance, on their own timelines and with their own documentary demands, including ultimate-beneficial-ownership disclosure down to the individuals behind your fund or holding structure. A deal can clear competition review and still stall on a health-authority licence transfer, or the reverse. The two workstreams need to be sequenced together from day one, not handled by separate teams who meet at closing.

Add regulatory runway to every UAE healthcare term sheet from now on. That means a competition assessment during diligence, a defensible relevant-market position drafted before you file, UBO documentation assembled up front rather than chased at the end, and long-stop dates that reflect a suspensory review plus parallel health-authority consent. Reverse break provisions, conditionality and the allocation of clearance risk between buyer and seller all move up the negotiation agenda. Sellers who cannot show a clean, notifiable path will find buyers discount for the uncertainty.